Isogenica’s Blogs
Advantages of using VHH antibodies for CAR engineering
We explain the advantages of VHHs for CAR ectodomain targeting relative to traditional scFvs including size, solubility, and VHHs unique “magic finger” CDR3 domain.
Small antibodies, big libraries
As VHH antibody experts, we’re big proponents of using synthetic libraries for antibody discovery. But what exactly are the benefits? Do they even produce good molecules? And what do you gain by having access to the largest and most diverse VHH libraries on the market?
Appetite for destruction: ‘Plug and play’ targeted protein degradation using synthetic VHH antibodies to take out tricky targets
Novel VHH protein degraders developed using Isogenica’s VHH antibody libraries show anti-tumour activity in vivo.
‘Intrabodies’ – Isogenica’s VHH antibodies improve heart function when delivered intracellularly
Our VHH antibodies have been put to the test as a potential new therapy for heart failure in an early-stage study from AstraZeneca published in Nature Communications. In a step forward for intracellular biotherapeutics, this early stage investigational research also used a viral vector to deliver our VHH antibodies directly inside heart cells.
2-for-1 VHH antibody engineering
When a partner needed VHH antibody engineering fast, we developed a method to humanise and affinity mature the antibodies in a single step.
VHH Humanisation
VHH humanisation can be a challenge. Here, we compare two methods – safe-but-slow rational humanisation and fast-but-risky CDR grafting. We also explore the impact of synthetic versus immune-derived frameworks.
Llamas: leading the pack in new cancer therapy, BioScience Today’s article on Isogenica’s VHH discovery
Llamas: leading the pack in new cancer therapy, BioScience Today’s article on Isogenica’s VHH discovery
Small and mighty – VHH ‘bolt-ons’ to expand therapeutic functionality
Small antibody building blocks: VHHs or “Nanobodies” are single domain antibodies about 1/10th the size of an IgG. Combined with their robust biophysical properties and high solubiltiy, the simplicity of these molecules…
The golden age of bi-specific antibodies is here
Bi-specific antibodies (BsAbs) – antibodies that can recognise two different epitopes on either the same or different antigens – have been around for a long time. However, in the past few years we’ve seen a renaissance in the design and application of these molecules.
On the Origin of VHHs: Student serendipity and coincidental camels
We explain how VHHs – small format single-domain antibody fragments – have a range of unique properties that make them ideal for enhancing the therapeutic potential of conventional IgG antibodies.